Hyperthermic intraperitoneal chemotherapy in gastric cancer

Indications and technical notes

Gianni Mura, Orietta Federici, Alfredo Garofalo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.

Original languageEnglish
Title of host publicationSurgery in the Multimodal Management of Gastric Cancer
PublisherSpringer-Verlag Italia s.r.l.
Pages107-112
Number of pages6
Volume9788847023185
ISBN (Print)9788847023185, 8847023173, 9788847023178
DOIs
Publication statusPublished - Nov 1 2012

Fingerprint

Stomach Neoplasms
Carcinoma
Drug Therapy
Peritoneal Diseases
Recurrence
Survival
Therapeutics
Palliative Care
Ascites
Neoplasms

Keywords

  • Cytoreductive surgery
  • Gastric cancer
  • HIPEC
  • Hyperthermia, induced
  • Hyperthermic intraperitoneal chemotherapy
  • Micrometastasis
  • Molecular biology
  • Peritoneal carcinomatosis
  • Randomized controlled trials
  • RT-PCR
  • Surgical cytoreduction
  • Surgical resection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mura, G., Federici, O., & Garofalo, A. (2012). Hyperthermic intraperitoneal chemotherapy in gastric cancer: Indications and technical notes. In Surgery in the Multimodal Management of Gastric Cancer (Vol. 9788847023185, pp. 107-112). Springer-Verlag Italia s.r.l.. https://doi.org/10.1007/978-88-470-2318-5_15

Hyperthermic intraperitoneal chemotherapy in gastric cancer : Indications and technical notes. / Mura, Gianni; Federici, Orietta; Garofalo, Alfredo.

Surgery in the Multimodal Management of Gastric Cancer. Vol. 9788847023185 Springer-Verlag Italia s.r.l., 2012. p. 107-112.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mura, G, Federici, O & Garofalo, A 2012, Hyperthermic intraperitoneal chemotherapy in gastric cancer: Indications and technical notes. in Surgery in the Multimodal Management of Gastric Cancer. vol. 9788847023185, Springer-Verlag Italia s.r.l., pp. 107-112. https://doi.org/10.1007/978-88-470-2318-5_15
Mura G, Federici O, Garofalo A. Hyperthermic intraperitoneal chemotherapy in gastric cancer: Indications and technical notes. In Surgery in the Multimodal Management of Gastric Cancer. Vol. 9788847023185. Springer-Verlag Italia s.r.l. 2012. p. 107-112 https://doi.org/10.1007/978-88-470-2318-5_15
Mura, Gianni ; Federici, Orietta ; Garofalo, Alfredo. / Hyperthermic intraperitoneal chemotherapy in gastric cancer : Indications and technical notes. Surgery in the Multimodal Management of Gastric Cancer. Vol. 9788847023185 Springer-Verlag Italia s.r.l., 2012. pp. 107-112
@inbook{841931c91308412a8d01b7d9a6fadce5,
title = "Hyperthermic intraperitoneal chemotherapy in gastric cancer: Indications and technical notes",
abstract = "Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.",
keywords = "Cytoreductive surgery, Gastric cancer, HIPEC, Hyperthermia, induced, Hyperthermic intraperitoneal chemotherapy, Micrometastasis, Molecular biology, Peritoneal carcinomatosis, Randomized controlled trials, RT-PCR, Surgical cytoreduction, Surgical resection",
author = "Gianni Mura and Orietta Federici and Alfredo Garofalo",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/978-88-470-2318-5_15",
language = "English",
isbn = "9788847023185",
volume = "9788847023185",
pages = "107--112",
booktitle = "Surgery in the Multimodal Management of Gastric Cancer",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - CHAP

T1 - Hyperthermic intraperitoneal chemotherapy in gastric cancer

T2 - Indications and technical notes

AU - Mura, Gianni

AU - Federici, Orietta

AU - Garofalo, Alfredo

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.

AB - Synchronous and metachronous peritoneal carcinomatosis (PC) is the most important issue in gastric cancer (GC) recurrence. Progress in the therapeutic challenge posed by PC has been made through a new treatment consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), developed over the last two decades. This chapter provides a review of the literature and recent results. Current indications for HIPEC in GC are: for curative purposes in addition to CRS in the treatment of PC; as palliative treatment for otherwise untreatable ascites; and as adjuvant treatment in the absence of PC for tumors infiltrating the serosal layer. There is abundant evidence that a multimodality approach offers survival benefits over surgery alone. In selected patients and in experienced centers, HIPEC after radical CRS can prolong survival and reduce peritoneal recurrences. The early identification of GC patients at high risk for peritoneal disease is a task for the future.

KW - Cytoreductive surgery

KW - Gastric cancer

KW - HIPEC

KW - Hyperthermia, induced

KW - Hyperthermic intraperitoneal chemotherapy

KW - Micrometastasis

KW - Molecular biology

KW - Peritoneal carcinomatosis

KW - Randomized controlled trials

KW - RT-PCR

KW - Surgical cytoreduction

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=84930811520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930811520&partnerID=8YFLogxK

U2 - 10.1007/978-88-470-2318-5_15

DO - 10.1007/978-88-470-2318-5_15

M3 - Chapter

SN - 9788847023185

SN - 8847023173

SN - 9788847023178

VL - 9788847023185

SP - 107

EP - 112

BT - Surgery in the Multimodal Management of Gastric Cancer

PB - Springer-Verlag Italia s.r.l.

ER -